00000nam 2200000za 4500 9.843746 CaOODSP 20221107152607 cr ||||||||||| 170915s2017 oncd #ob f000 0 eng d 978-0-660-09724-4 CaOODSP eng n-cn--- HP40-192/2017E-PDF Update on HIV-1 strain and transmitted drug resistance in Canada [electronic resource] : findings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013. Findings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013 Ottawa : Public Health Agency of Canada, 2017. vi, 39 p. : graphs "Publication date: November 2017." "Protecting and empowering Canadians to improve their health"--Cover. Issued also in French under title: Mise à jour sur les souches du VIH-1 et la pharmacorésistance transmise au Canada : résultats du Programme canadien de surveillance des souches et de la résistance aux médicaments ayant trait au VIH, 2012-2013. Includes bibliographical references. "HIV is a significant public health challenge. A key component in monitoring the epidemicis surveillance on HIV subtypes and drug resistance. Subtype B historically constituted over 95% of new diagnoses in Canada; however, the proportion of non-B subtypes has gradually been increasing and now represents about 20% of new diagnoses. Surveillance on HIV subtypes informs vaccine development and provides the opportunity to examine potential variation in transmission risk and treatment success by subtype. Moreover, national HIV drug resistance surveillance is important since transmission of drug-resistant HIV impacts treatment and also prevention and control activities. In 1998, the Public Health Agency of Canada (PHAC) created the Canadian HIV Strain and Drug Resistance Surveillance Program (SDR Program) to monitor HIV-1 subtypes and pre-treatment antiretroviral resistance in Canada. Six provinces collaborate with PHAC on this initiative: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Nova Scotia"--Executive summary, p. 3. gccst AIDS (disease) gccst Drug use gccst Immunization Public Health Agency of Canada. Mise à jour sur les souches du VIH-1 et la pharmacorésistance transmise au Canada (CaOODSP)9.843751 PDF 1.21 MB https://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-192-2017-eng.pdf Pub.: 170240